Fedratinib and Ruxolitinib Improve Survival as Treatment of Myelofibrosis
Ruben Mesa, MD, discusses the role of ruxolitinib and fedratinib, first-generation JAK inhibitors, as treatment of patients with myelofibrosis.
Ruben Mesa, MD, the director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the role of ruxolitinib (Jakafi) and fedratinib (Inrebic), first-generation JAK inhibitors, as treatment of patients with myelofibrosis (MF).
Both fedratinib and ruxolitinib are available as frontline agents for patients with MF. In this setting, both drugs have shown to have the ability to improve splenomegaly and symptoms in patients with intermediate- and advanced-risk disease, says Mesa.
Additionally, investigators believe there is a likelihood to improve and extend survival with these agents in patients with MF with less debilitation. In addition, there may also be long-term effects in patients with bone marrow histologic features, as well as more subtle evidence of disease modification.
<< View more resources and information regarding myeloproliferative neoplasms
FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML
November 15th 2024The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly diagnosed Ph-positive CP- and AP-CML, or for those resistant or intolerant to prior therapy, including imatinib.
Read More
